C24-Ceramide Drives Gallbladder Cancer Progression Through Directly Targeting Phosphatidylinositol 5-Phosphate 4-Kinase Type-2 Gamma to Facilitate Mammalian Target of Rapamycin Signaling Activation.
Yonglong ZhangHui WangTao ChenHaolu WangXiaowen LiangYuchen ZhangJinlin DuanShenjiao QianKe QiaoLei ZhangYanfeng LiuJian WangPublished in: Hepatology (Baltimore, Md.) (2020)
Our findings highlight the clinical relevance of ceramide metabolism with GBC progression and identify C24-Ceramide as a diagnostic biomarker for GBC. We propose that PIP4K2C is indispensable for C6-Ceramide as a potential therapeutic intervention for GBC through a direct competition with C24-Ceramide.